Obagi Medical, under the umbrella of Waldencast (WALD, Financial), has unveiled its newest innovation in skincare: the Retinol + PHA Refining Night Cream. This product is designed to significantly enhance skin rejuvenation processes.
The cream features Entrapped Retinol, known for its potent cell renewal capabilities, paired with Polyhydroxy Acid Gluconolactone, which gently exfoliates the skin. This combination is intended to increase skin cell turnover and bolster the skin's natural barrier.
Users can expect a smoother, more refined, and evenly toned complexion as a result of this advanced formulation. Obagi Medical continues to advance in the dermatological field by developing products that incorporate innovative scientific research and proven ingredients.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Waldencast PLC (WALD, Financial) is $4.85 with a high estimate of $6.00 and a low estimate of $3.40. The average target implies an upside of 76.36% from the current price of $2.75. More detailed estimate data can be found on the Waldencast PLC (WALD) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Waldencast PLC's (WALD, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
